Apogee reports positive Phase 2 52-week zumilokibart data; durable maintenance with 3- and 6-month dosing

Apogee Therapeutics, Inc.

EASI-75 maintained in 75% (3-month) and 85% (6-month) of Week 16 responders; vIGA 0/1 maintained in 86% and 78%.
Deepening of response across all endpoints over 52 weeks in the full zumilokibart-treated population.
Safety profile consistent with class; common TEAEs: noninfective conjunctivitis (13.4%), URTI (12.6%), nasopharyngitis (9.2%).
Part B 16-week induction data expected Q2 2026; Phase 3 initiation in 2H 2026; potential commercial launch in 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.